News & Media
Press Center & More

Up-to-date press releases and statements in all categories, as well as materials for journalists.

Go to press releases
Sep 12, 2023
Statement
COVID-19

U.S. CDC and Advisory Committee Recommend Use of Authorized and Approved 2023-2024 Monovalent XBB COVID-19 Vaccines

Read full article
Download
Sep 11, 2023
Statement

Novavax Continues Progress Towards Delivery of its Protein-based Non-mRNA XBB COVID Vaccine to U.S.

Read full article
Download
Sep 8, 2023
Corporate and finance

Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)

Read full article
Download
All press releases

Media contact

Email: [email protected]
Phone: (202) 709-5563

A practitioner priming a hypodermic needle
Patient getting shot in arm
Syringe and vial

Images, videos, and files for media use

Extensive materials for members of the press, including broadcast, online, film, radio and print journalists.

Explore & download

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Who we are